MX364626B - Péptidos miméticos. - Google Patents

Péptidos miméticos.

Info

Publication number
MX364626B
MX364626B MX2015005761A MX2015005761A MX364626B MX 364626 B MX364626 B MX 364626B MX 2015005761 A MX2015005761 A MX 2015005761A MX 2015005761 A MX2015005761 A MX 2015005761A MX 364626 B MX364626 B MX 364626B
Authority
MX
Mexico
Prior art keywords
mimetic peptides
methods
mimetic
peptides
apolipoprotein
Prior art date
Application number
MX2015005761A
Other languages
English (en)
Other versions
MX2015005761A (es
Inventor
Vuilleumier Nicolas
Pagano Sabrina
Hartley Oliver
Gaertner Hubert
Camillo Teixeira Priscila
cutler Paul
Ferber Philippe
Original Assignee
Les Hopitaux Univ De Geneve
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Les Hopitaux Univ De Geneve filed Critical Les Hopitaux Univ De Geneve
Publication of MX2015005761A publication Critical patent/MX2015005761A/es
Publication of MX364626B publication Critical patent/MX364626B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/775—Apolipopeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)

Abstract

La presente invención se refiere a péptidos miméticos de epítope (s) de la Apolipoproteína A-I, inmunoensayos para diagnóstico que comprenden tales péptidos miméticos, así como métodos para diagnosticar y métodos para prevenir y/o tratar una enfermedad cardiovascular.
MX2015005761A 2012-11-06 2013-11-06 Péptidos miméticos. MX364626B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12191474 2012-11-06
PCT/IB2013/059948 WO2014072916A1 (en) 2012-11-06 2013-11-06 Mimetic peptides

Publications (2)

Publication Number Publication Date
MX2015005761A MX2015005761A (es) 2015-08-12
MX364626B true MX364626B (es) 2019-05-03

Family

ID=47115623

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015005761A MX364626B (es) 2012-11-06 2013-11-06 Péptidos miméticos.

Country Status (11)

Country Link
US (1) US10087234B2 (es)
EP (1) EP2917234B1 (es)
JP (1) JP6499967B2 (es)
KR (1) KR102215175B1 (es)
CN (1) CN104768970B (es)
BR (1) BR112015010276A2 (es)
CA (1) CA2888657C (es)
ES (1) ES2859559T3 (es)
MX (1) MX364626B (es)
RU (1) RU2662973C2 (es)
WO (1) WO2014072916A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11136372B2 (en) 2017-01-19 2021-10-05 The United States Of America, As Represented By The Secretary, Dept. Of Health & Human Services ApoC-II mimetic peptides
JP7434169B2 (ja) 2018-04-10 2024-02-20 サノフィ－アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 固相からの固相結合ペプチドの切断方法
SG11202010016QA (en) * 2018-04-10 2020-11-27 Sanofi Aventis Deutschland Lixisenatide synthesis with capping
CN108948158B (zh) * 2018-07-21 2021-06-15 河南大学 四连接素模拟肽tnp及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6664230B1 (en) 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
SE0103754L (sv) * 2001-04-05 2002-10-06 Forskarpatent I Syd Ab Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid
CA2549529A1 (en) * 2003-12-15 2005-06-30 The Regents Of The University Of California Helical synthetic peptides that stimulate cellular cholesterol efflux
US7972770B2 (en) * 2005-08-16 2011-07-05 Memorial Sloan-Kettering Cancer Center Methods of detection of cancer using peptide profiles
EP2170947A4 (en) * 2007-06-20 2010-07-14 Merck Sharp & Dohme ApoA-1 peptidomimetic
US8957026B2 (en) * 2010-09-22 2015-02-17 President And Fellows Of Harvard College Beta-catenin targeting peptides and uses thereof
WO2012149563A1 (en) 2011-04-29 2012-11-01 Kinemed, Inc. Chemical modification of apolipoprotein mimetic peptides for the production of therapeutic agents

Also Published As

Publication number Publication date
US10087234B2 (en) 2018-10-02
CA2888657A1 (en) 2014-05-15
CN104768970A (zh) 2015-07-08
JP2016505514A (ja) 2016-02-25
WO2014072916A1 (en) 2014-05-15
BR112015010276A2 (pt) 2019-10-15
RU2015121688A (ru) 2016-12-27
KR20150082350A (ko) 2015-07-15
KR102215175B1 (ko) 2021-02-15
MX2015005761A (es) 2015-08-12
CN104768970B (zh) 2019-11-15
JP6499967B2 (ja) 2019-04-10
ES2859559T3 (es) 2021-10-04
US20150291682A1 (en) 2015-10-15
CA2888657C (en) 2022-05-03
RU2662973C2 (ru) 2018-07-31
EP2917234A1 (en) 2015-09-16
EP2917234B1 (en) 2020-12-02

Similar Documents

Publication Publication Date Title
NZ700823A (en) Antibodies against claudin 18.2 useful in cancer diagnosis
WO2014124334A3 (en) Transthyretin antibodies and uses thereof
CY1122978T1 (el) Αντισωματα εναντι-vla-4
WO2015061634A3 (en) Biomarkers and diagnostic methods for alzheimer's disease and other neurodegenerative disorders
WO2016014974A3 (en) Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
CL2014001994A1 (es) Polipeptido mimético de apelina sintéticos para el tratamiento e insuficiencia cardiaca; composicion farmacéutica que comprende dicho polipeptido.
WO2014031859A3 (en) Compositions and methods relating to blood-based biomarkers of breast cancer
SG10201902924RA (en) Antibodies that bind ebola glycoprotein and uses thereof
EA201791693A1 (ru) Гетеродимерные иммуноглобулины
WO2014152157A3 (en) Methods and compositions for the generation and use of conformation-specific antibodies
MX357202B (es) Composicion de particula tipo virus.
MX2015012872A (es) Anticuerpos anti-tau y metodos de uso.
WO2012009567A3 (en) Biomarkers for diagnosis of stroke and its causes
NZ761537A (en) Anti-human ox40l antibodies, uses & methods
MY162323A (en) Anticoagulant antidotes
IN2014DN05885A (es)
WO2011106322A3 (en) Biomarkers for acute ischemic stroke
MX2014012978A (es) Regiones de anticuerpo modificado y sus usos.
UA106900C2 (uk) Агоністичний dr5-зв'язувальний поліпептид
MX2023006415A (es) Anticuerpos, usos y metodos.
WO2013106747A3 (en) Methods and compositions for the treatment and diagnosis of thyroid cancer
TN2013000373A1 (en) Pharmaceutical formulation comprising inositol
WO2016057683A3 (en) Novel anti-nodal antibodies and methods of using same
WO2015023508A8 (en) Methods for improving asthma symptoms using benralizumab
MX364626B (es) Péptidos miméticos.

Legal Events

Date Code Title Description
FG Grant or registration